Gupta N, Song H, Wu W, Ponce RK, Lin YK, Kim JW, Small EJ, Feng FY, Huang FW, Okimoto RA. The CIC-ERF co-deletion underlies fusion independent activation of ETS family member, ETV1, to drive prostate cancer progression.

Luck C, You K, Okimoto RA, Sirota M. Transcriptional fidelity enhances cancer cell line selection in pediatric cancers.:


Kim JW, Luck C, Wu W, Ponce RK, Lin YK, Gupta N, Okimoto RA. Capicua Suppresses  YAP1 To Limit Tumorigenesis and Maintain Drug Sensitivity in Human Cancer. Cell Reports, 2022.

Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Ali S, Kerr DL, Olivas V, Shue J, Rotow J, Mayekar M, Haderk F, Chatterjee N, Urisman A, Kirichok Y, Tan DSW, Rosell R, Okimoto RA, Bivona TG. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer. J Clin Invest, 2022.

Ponce RK*, Thomas NJ*, Bui N, Kondo T, Okimoto RA. WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma. *co-first authors. JCI Insight, 2022.


Wustrack RW, Shao E, Sheridan J, Zimel M, Cho SJ, Horvai A, Luong D, Kwek S, Fong L*, Okimoto RA*. Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma. Cancer Immunology, Immunotherapy, 2021. *corresponding author 

Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JSSingle-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. 

Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Holzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Gruner BM, Bivona TG, Schramm A, Schüler M. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis 9, 102 2020 

Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA*. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proc. Natl. Acad. Sci.117 (34) 20776-20784, 2020. *corresponding author.​


Okimoto RA*, Wu W, Nanjo S, Olivas V, Lin YK, Ponce R, Oyama R, Kondo T, Bivona TG*. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019 Jul 22;130. pii: 126366. *corresponding author.

Fish L, Navickas A, Culbertson B, Xu Y, Nguyen HCB, Zhang S, Hochman M, Okimoto R, Dill BD, Molina H, Najafabadi HS, Alarcon C, Ruggero D, and Goodarzi H. Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay. Mol Cell. 2019 Jun 25. pii: S1097-2765(19)30434-4.


Okimoto RA and Bivona TG. Metastasis. From head to Tail. Cell Cycle. 19;16(6):487-488, 2017.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma H, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. Inactivation of Capicua drives cancer metastasis. Nat Genet. 49(1):87-96, 2017.


Okimoto RA*, Lin L*, Olivas V, Markegard E, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in BRAF- mutant lung cancer. Proc Natl Acad Sci U S A. 113(47):13456-13461, 2016. *Co-author

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 380(1):144-52, 2016.

Okimoto RA, Bivona TG. Tracking down response and resistance to TRK inhibitors. Cancer Discov 6(1):14-6, 2016.


Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK- positive lung cancer. Nat Med 21(9):1038-47, 2015.

Okimoto RA, BIvona TG. AXL receptor tyrosine kinase as a therapeutic target in lung cancer.Lung Cancer: Targets and Therapy. 6:27-34, 2015.

Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Brain Pathol. 25(1): 111-2, 2015.


Okimoto RA, Bivona TG. Recent advances in personalized, precision lung cancer medicine. Per Med. 11(3):309-321, 2014


Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 18(2): 89-97, 2011.


Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, and Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.Blood.111(9): 4716-22, 2008.


Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Toby EM, Smith SL, Isselbacher KJ, and Shioda T. Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res. 66(20): 10153-61, 2006.

Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuch CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA and Bell DW. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. Clin Cancer Res.12(14): 4283-4287, 2006.

Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX and Haber DA. Frequent Met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res.66(7): 3452-55, 2006.

Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, and Haber DA. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA- 665752. Proc Natl Acad Sci U S A. 103(7): 2316-21, 2006.


Lynch HT, de la Chapelle A, Hampel H, Wagner A, Fodde R, Lynch JF, Okimoto R, Clark MB, Coronel S, Trowonou A, Fu YX, Haynatzki GR, Gong G. The American founder mutation for Lynch syndrome: Prevalence estimates and implications. Cancer. 106(2): 448-452, 2005.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma S, Brannigan BW, Mohapatra G, Settleman J, Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 37(12): 1315-1316, 2005.

Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR . Clin Cancer Res. 11(22): 8105-8108, 2005.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenshneider MJ, Krebs AD, Iacona RB, Johnson DH, Giaccone G, Hebrst RS, Rosell R, Manegold C, Fukuoka M, Kris MG, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplifications in non-small cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 23(31): 8081-8092, 2005.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch T, Sharma SV, Settleman J, Haber DA. Irreversible inhibitors of the epidermal growth factor receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 102(21):7665-70, 2005.


Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small- Cell Lung Cancer to Gefitinib. N Engl J Med. 350(21):2129-39, 2004.

Lynch HT, Coronel SM, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrows A, Wijnen J, van der Klift H, Franken P, Wagner A, Fodde R, de la Chapelle A. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 291(6): 718-24, 2004.


Wagner A, Barrows A, Wijnen JT, van der Klift H, Franken PF, Verkuijlen P, Nakagawa H, Geugien M, Jaghmohan-Changur S, Breukel C, Meijers-Heijboer H, Morreau H, van Puijenbroek M, Burn J, Coronel S, Kinarski Y, Okimoto R, Watson P, Lynch JF, de la Chapelle A, Lynch HT, Fodde R. Molecular analysis of Hereditary Non-Polyposis Colorectal Cancer in the United States: High Mutation Detection Rate Among Clinically Selected Families and Characterization of an American Founder Genomic Deletion of the MSH2 Gene. Am J Hum Genet. 72(5):1088-1100, 2003.